127 related articles for article (PubMed ID: 8020528)
21. [Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke].
Dézsi L; Kis-Varga I; Nagy J; Komlódi Z; Kárpáti E
Acta Pharm Hung; 2002; 72(2):84-91. PubMed ID: 12498034
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of vinpocetine (Cavinton) in dog.
Polgár M; Vereczkey L
Pol J Pharmacol Pharm; 1984; 36(4):407-12. PubMed ID: 6527972
[TBL] [Abstract][Full Text] [Related]
23. Metabolism of ethyl apovincaminate in the rat.
Vereczkey L; Szporny L
Arzneimittelforschung; 1976; 26(10a):1933-8. PubMed ID: 1037219
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.
Nyakas C; Felszeghy K; Szabó R; Keijser JN; Luiten PG; Szombathelyi Z; Tihanyi K
CNS Neurosci Ther; 2009; 15(2):89-99. PubMed ID: 19492990
[TBL] [Abstract][Full Text] [Related]
25. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
26. Determination of apovincaminic acid in human plasma by gas-liquid chromatography.
Polgár M; Vereczkey L
J Chromatogr; 1982 May; 241(1):29-32. PubMed ID: 7107795
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous evaluation of apovincaminic acid esters and their metabolite apovincaminic acid by solvent partition and GLC in biological samples. Preliminary data with MR 711.
Marzo A; Quadro G; Stradi R; Saccarello ML; Molteni L; Bruno G
Arzneimittelforschung; 1981; 31(10):1681-4. PubMed ID: 7198444
[TBL] [Abstract][Full Text] [Related]
28. Systemic exposure of vinpocetine in pregnant Sprague Dawley rats following repeated oral exposure: An investigation of fetal transfer.
Waidyanatha S; Toy H; South N; Gibbs S; Mutlu E; Burback B; McIntyre BS; Catlin N
Toxicol Appl Pharmacol; 2018 Jan; 338():83-92. PubMed ID: 29155086
[TBL] [Abstract][Full Text] [Related]
29. Brain uptake and plasma metabolism of [11C]vinpocetine: a preliminary PET study in a cynomolgus monkey.
Gulyás B; Halldin C; Karlsson P; Chou YH; Swahn CG; Bönöck P; Paróczai M; Farde L
J Neuroimaging; 1999 Oct; 9(4):217-22. PubMed ID: 10540601
[TBL] [Abstract][Full Text] [Related]
30. Development of a sensitive enzyme immunoassay for the determination of vinpocetine in human plasma.
Reck B; Dingler E; Lohmann A
Arzneimittelforschung; 1992 Oct; 42(10):1171-4. PubMed ID: 1472136
[TBL] [Abstract][Full Text] [Related]
31. PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects.
Gulyás B; Halldin C; Sandell J; Karlsson P; Sóvágó J; Kárpáti E; Kiss B; Vas A; Cselényi Z; Farde L
Acta Neurol Scand; 2002 Dec; 106(6):325-32. PubMed ID: 12460136
[TBL] [Abstract][Full Text] [Related]
32. Effects of VA-045, a novel apovincaminic acid derivative, on age-related impairment evidence in electroencephalograph, caudate spindle, a passive avoidance task and cerebral blood flow in rats.
Okuyama S; Hashimoto-Kitsukawa S; Ogawa S; Imagawa Y; Kawashima K; Kawashima Y; Araki H; Otomo S
Gen Pharmacol; 1994 Nov; 25(7):1311-20. PubMed ID: 7896040
[TBL] [Abstract][Full Text] [Related]
33. The absorption and excretion of the peripheral vasodilator 14C-mecinarone, (14C-6809 MD) in rat, dog and man.
Hawkins DR; Weston KT; Chasseaud LF; Darragh A; O'Kelly A
Eur J Drug Metab Pharmacokinet; 1980; 5(3):135-43. PubMed ID: 7202431
[TBL] [Abstract][Full Text] [Related]
34. Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography-tandem mass spectrometry.
Xia HM; Su LN; Guo JW; Liu GM; Pang ZQ; Jiang XG; Chen J
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jul; 878(22):1959-66. PubMed ID: 20561830
[TBL] [Abstract][Full Text] [Related]
35. Design, Characterization, and Application of a pH-Triggered In Situ Gel for Ocular Delivery of Vinpocetine.
Ma Q; Luo R; Zhang H; Dai M; Bai L; Fei Q; Lei F; He N
AAPS PharmSciTech; 2020 Sep; 21(7):253. PubMed ID: 32888086
[TBL] [Abstract][Full Text] [Related]
36. Biotransformation of the organic nitrate trans-N-(4-nitroxycyclohexyl)acetamide in dogs.
Zell C; Neidlein R; Strein K
Arzneimittelforschung; 1994 Sep; 44(9):1021-8. PubMed ID: 7986238
[TBL] [Abstract][Full Text] [Related]
37. Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability.
Luo Y; Chen D; Ren L; Zhao X; Qin J
J Control Release; 2006 Aug; 114(1):53-9. PubMed ID: 16828192
[TBL] [Abstract][Full Text] [Related]
38. Absorption, distribution, metabolism and excretion of YM466, a novel factor Xa inhibitor, in rats.
Mano Y; Sonoda T; Nakamura E; Usui T; Kamimura H
Biopharm Drug Dispos; 2004 Sep; 25(6):253-60. PubMed ID: 15334624
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of vinpocetine in humans.
Vereczkey L; Czira G; Tamás J; Szentirmay Z; Botár Z; Szporny L
Arzneimittelforschung; 1979; 29(6):957-60. PubMed ID: 582791
[TBL] [Abstract][Full Text] [Related]
40. Protective action of vinpocetine against experimentally induced gastric damage in rats.
Nosálová V; Machová J; Babulová A
Arzneimittelforschung; 1993 Sep; 43(9):981-5. PubMed ID: 8240463
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
